Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2
نویسنده
چکیده
2 Sentinel lymph node biopsy for early cervical cancer: Results of a randomized prospective, multicenter study (Senticol 2) comparing adding pelvic lymph node dissection vs. sentinel node biopsy only P. Mathevet1, F. Lecuru2, L. Magaud3 and F. Bouttitie4 1CHU Vaudois, Lausanne, Switzerland, 2Hôpital Européen Georges-Pompidou, Paris, France, 3Hospices Civils de Lyon, Bron, France, 4Hospices Civils de Lyon, Pierre-Bénite, France Abstract 3 Isolated tumor cells (ITC) identified by sentinel lymph node (SLN) mapping in endometrial cancer: Does adjuvant treatment matter? M. Plante1, J. Stanleigh1, M.C. Renaud2, A. Sebastianelli2 and J. Grégoire2 1Laval University, L’Hotel-Dieu de Quebec, Quebec City, QC, Canada, 2L’Hotel-Dieu de Quebec, Quebec City, QC, Canada3 Isolated tumor cells (ITC) identified by sentinel lymph node (SLN) mapping in endometrial cancer: Does adjuvant treatment matter? M. Plante1, J. Stanleigh1, M.C. Renaud2, A. Sebastianelli2 and J. Grégoire2 1Laval University, L’Hotel-Dieu de Quebec, Quebec City, QC, Canada, 2L’Hotel-Dieu de Quebec, Quebec City, QC, Canada Abstract 4 Comparison of long term impact and clinical outcomes of reduced dose vs. standard dose quadrivalent human papillomavirus vaccine in the United States: A database study B. Zeybek and A. Rodriguez The University of Texas Medical Branch, Galveston, TX, USA 2017 Abstracts4 Comparison of long term impact and clinical outcomes of reduced dose vs. standard dose quadrivalent human papillomavirus vaccine in the United States: A database study B. Zeybek and A. Rodriguez The University of Texas Medical Branch, Galveston, TX, USA 2017 Abstracts Abstracts will be made publically available on the SGO meeting app and website at the start of the session during which they are presented.s will be made publically available on the SGO meeting app and website at the start of the session during which they are presented.
منابع مشابه
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
Rucaparib is a potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) proteins (PARP-1, PARP-2 and PARP-3) that play an important role in repairing DNA damage and maintaining genomic stability. Tumors with mutations in BRCA1/2 or other homologous recombination deficiency (HRD) genes are particularly sensitive to PARP inhibitors because of "synthetic lethality", whereby a therape...
متن کاملRucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor. Phase I and II studies demonstrated clinical efficacy in both BRCA-mutated (inclusive of germline and somatic) ovarian tumors and ovarian tumors with homologous recombination deficiency (HRD) loss of heterozygosity (LOH). Rucaparib has received the US Food and Drug Administration (FDA) approva...
متن کاملA Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.
Purpose: Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I-II study was the first to evaluate single-agent oral rucaparib at multiple doses.Experimental Design: Part 1 (phase I) sought to determine the MTD, recommended phase II dose (RP2D), and pharmacokinetics of oral rucaparib administered in 21-day continuous cycles in patients with advanced solid tumors. Part 2A (phas...
متن کاملPARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Homologous recombination (HR) and base excision repair (BER) are two of the major DNA-repair pathways. The proteins encoded by breast-related cancer antigen (BRCA) and poly(adenosine diphosphate-ribose) polymerases (PARP) are involved in HR and BER, respectively. Tumors with HR deficiency, including those in BRCA mutation carriers, are sensitive to BER blockade via PARP inhibitors. These repres...
متن کاملNew perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
Ovarian cancer (OC) is the seventh most common cancer in women. Although women diagnosed with OC are usually treated frontline with platinum-based chemotherapy, most of them relapse once treatment is halted. Therefore, maintenance therapies have been developed to secure the response and delay further chemotherapy. There are two established maintenance therapies for women affected by platinum-se...
متن کامل